Abdullah Alajati

4PUBLICATIONS
66CO-AUTHORS
Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

Sort by Publication Date:
|Jun 13, 2025
The Antibody-Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma.

Racha Hosni, Niklas Klümper, Christine Sanders

|Jan 04, 2024
Adipocyte Precursor-Derived NRG1 Promotes Resistance to FGFR Inhibition in Urothelial Carcinoma.

Sana Hosni, Viola Kilian, Niklas Klümper

|Dec 19, 2022
Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance.

Niklas Klümper, Damian J Ralser, Jörg Ellinger

Pageof 1

Frequent Collaborators

4 joint publications

Niklas Klümper

4 joint publications

Michael Hölzel

4 joint publications

Marieta Toma

3 joint publications

Damian J Ralser

3 joint publications

Sana Hosni

3 joint publications

Glen Kristiansen

2 joint publications

Markus Eckstein

2 joint publications

Manuel Ritter

2 joint publications

Maria A Gonzalez-Carmona

2 joint publications

Racha Hosni

Frequent Collaborators

4 joint publications

Niklas Klümper

4 joint publications

Michael Hölzel

4 joint publications

Marieta Toma

3 joint publications

Damian J Ralser

JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us

Top Related Videos

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on : Jul 12, 2018

8.8K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on : Feb 16, 2015

21.4K
Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on : Oct 27, 2020

13.0K
See more related videos

Top Related Videos

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on : Jul 12, 2018

8.8K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on : Feb 16, 2015

21.4K
Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on : Oct 27, 2020

13.0K
See more related videos